Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026)

Sarepta Therapeutics' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 58.04% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (down 58.04% YoY), while the FY2025 annual figure was $83.9 million, down 74.18% from the prior year.
• Non-Current Deffered Revenue was $136.4 million for Q1 2026 at Sarepta Therapeutics, up from $83.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $552.2 million in Q1 2022 to a low of $83.9 million in Q4 2025.
• Historically, Non-Current Deffered Revenue has averaged $387.5 million across 5 years, with a median of $437.0 million in 2023.
• Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2025; the steepest drop was 74.18% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $485.0 million in 2022, then fell by 9.9% to $437.0 million in 2023, then dropped by 25.63% to $325.0 million in 2024, then tumbled by 74.18% to $83.9 million in 2025, then soared by 62.5% to $136.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $136.4 million (Q1 2026), $83.9 million (Q4 2025), and $325.0 million (Q1 2025), per Business Quant data.